JY
SPRY icon

Jeff Yass’s ARS Pharmaceuticals SPRY Stock Holding History

Jeff Yass’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$468K Sell
58,413
-2,124
-4% -$18.3K ﹤0.01% 10072
2026
Q1 		$486K Buy
+60,537
New +$580K ﹤0.01% 9747
2025
Q3 		– Sell
-256,966
Closed -$3.69M – 13790
2025
Q2 		$4.48M Buy
256,966
+52,765
+26% +$761K ﹤0.01% 4175
2025
Q1 		$2.57M Buy
204,201
+32,816
+19% +$395K ﹤0.01% 4983
2024
Q4 		$1.81M Buy
171,385
+24,094
+16% +$337K ﹤0.01% 5549
2024
Q3 		$2.14M Buy
147,291
+121,790
+478% +$1.45M ﹤0.01% 5147
2024
Q2 		$217K Sell
25,501
-55,344
-68% -$491K ﹤0.01% 10178
2024
Q1 		$826K Sell
80,845
-172,571
-68% -$1.29M ﹤0.01% 7342
2023
Q4 		$1.39M Buy
253,416
+77,873
+44% +$341K ﹤0.01% 6179
2023
Q3 		$664K Buy
175,543
+24,183
+16% +$159K ﹤0.01% 7576
2023
Q2 		$1.01M Sell
151,360
-161,594
-52% -$1.08M ﹤0.01% 6644
2023
Q1 		$2.04M Buy
312,954
+267,008
+581% +$2.05M ﹤0.01% 5098
2022
Q4 		$392K Buy
+45,946
New +$298K ﹤0.01% 8437
2022
Q3 		– Sell
-151,582
Closed -$747K – 14071
2022
Q2 		$643K Buy
+151,582
New +$529K ﹤0.01% 7651

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Jeff Yass's SPRY Position: Q2 2026 in Review

Jeff Yass reduced its ARS Pharmaceuticals (SPRY) stake by 3.5% in Q2 2026, selling an estimated $18.3K and leaving 58,413 shares worth $468K. The position accounts for ﹤0.01% of the portfolio, ranked #10072.

Jeff Yass first reported a position in SPRY in Q2 2022 and has held it in 14 quarters since. The position peaked at $4.48M in Q2 2025. 205 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Jeff Yass held 58,413 shares of ARS Pharmaceuticals worth $468K as of Q2 2026.
  • Jeff Yass sold 2,124 ARS Pharmaceuticals shares in Q2 2026, an estimated $18.3K.
  • ARS Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10072 holding.
  • Jeff Yass first reported a position in ARS Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
  • Jeff Yass's ARS Pharmaceuticals position peaked at $4.48M in Q2 2025.
  • 205 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.